SUZHOU, China and ROCKVILLE, Md., Oct. 23, 2023 /PRNewswire/ Ascentage Pharma , a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B , and.
Media Release Median Overall Survival reaches 35.5 months in first-line treatment of metastatic non-small cell lung cancer patients expressing PD-L1 (TPS >1%), 23.4 months in patients with low PD-L1 expression (TPS 1-49%), and has not been reached in patients with high PD-L1 expression (TPS >50%), exceeding expectationsPromising Overall Survival, Overall Response Rate, Progression Free Survival, and Duration of Response visible across all PD-L1 subgroups (TPS <1%, ≥1%, 1-49%, and ≥50%), differen
17.10.2023 - FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) - Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and . Seite 1
Data include three late-breaking abstracts, underscoring Astellas efforts to potentially redefine expectations for patients across its oncology portfolio
TOKYO, Oct. 15, 2023 /PRNewswire/ .
Abstract highlights how NOX-A12 and radiotherapy remodel the immune tumor microenvironment in brain cancer patientsBERLIN (BUSINESS WIRE) Regulatory News:TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor micr.